Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MnP3
- Development stage
- Preclinical
- Lead developer
- Ivy Brain Tumor Center
- Modality
- Small Molecules
01
Overview
MnP3 is a next-generation, brain-penetrant manganese porphyrin-based superoxide dismutase (SOD) mimic. It is designed to protect normal brain tissue from radiation-induced damage by scavenging deleterious free radicals generated during radiotherapy. Unlike earlier SOD mimics, MnP3 is specifically engineered for enhanced blood-brain barrier (BBB) penetration and a favorable safety profile. Preclinical studies have demonstrated its ability to accumulate in the brain and significantly reduce radiation-induced DNA damage, lipid peroxidation, apoptosis, and microglia activation, potentially preventing long-term cognitive deficits associated with brain irradiation.
02
Targets
Misfolded SOD1
Beyond the preview
Go deeper on MnP3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MnP3.